Chi Hsien Chan

Chairman & Chief Executive Officer at Adimmune Corp.

Chi Hsien Chan

Chi Hsien Chan

Chairman & Chief Executive Officer at Adimmune Corp.

Biography

Founder of Enimmune Corp., Chi Hsien Chan currently is Chairman & Chief Executive Officer of Adimmune Corp. In the past Dr. Chan was Chairman of Enimmune Corp. Dr. Chan received a doctorate from Chung Shan Medical University and a doctorate from National Defense Medical Center.

Overview
Career Highlights

Enimmune Corp.
Adimmune Corp.

RelSci Relationships

65

Number of Boards

3

Relationships
RelSci Relationships are individuals Chi Hsien Chan likely has professional access to. A relationship does not necessarily indicate a personal connection.

President & Director at Adimmune Corp.

Relationship likelihood: Strong

Chief Executive Officer at Epoch Foundation

Relationship likelihood: Strong

Former Chairman & Chief Executive Officer at Adimmune Corp.

Relationship likelihood: Strong

Chief Executive Officer at Foxconn Image & Printing Product Pte Ltd.

Relationship likelihood: Strong

Vice President at Development Center for Biotechnology

Relationship likelihood: Strong

Chairman & President at TTY Biopharm Co. Ltd.

Relationship likelihood: Strong

Chief Operating Officer at Adimmune Corp.

Relationship likelihood: Strong

Chief Financial Officer & Company Secretary at Hon Hai Precision Ind. Co., Ltd.

Relationship likelihood: Strong

Chief Legal Affairs Officer at Adimmune Corp.

Relationship likelihood: Strong

General Manager, Head-Finance & Spokesman at Enimmune Corp.

Relationship likelihood: Strong

Paths to Chi Hsien Chan
Potential Connections via
Relationship Science
You
Chi Hsien Chan
Chairman & Chief Executive Officer at Adimmune Corp.
Career History
Chairman & Chief Executive Officer
2008 - Current

Adimmune Corp. engages in the manufacturing and sales of influenza vaccine. Its products include Trivalent Influenza vaccine, Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin. Its business scope includes research and development, processing, manufacturing, and trading of serum, vaccines, test reagents, biological agents and their bacterial liquids, and raw materials. The company was founded on December 22, 1965 and is headquartered in Taichung, Taiwan.

Chairman
Prior

Enimmune Corp. engages in the research, development of new drugs. Its products include EV71, Japanese encephalitis virus, EV71+CA16 bivalent, tetanus toxoid adsorbed, influenza, AH1N1, and pneumococcal vaccines. The company was founded on January 10, 2014 and is headquartered in Taipei, Taiwan.

Boards & Committees
Chairman & Chief Executive Officer
2008 - Current
Independent Director
2016 - 2019
Chairman
Prior
Investments
Details Hidden

Enimmune Corp. engages in the research, development of new drugs. Its products include EV71, Japanese encephalitis virus, EV71+CA16 bivalent, tetanus toxoid adsorbed, influenza, AH1N1, and pneumococcal vaccines. The company was founded on January 10, 2014 and is headquartered in Taipei, Taiwan.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Chi Hsien Chan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Chi Hsien Chan's profile does not indicate a business or promotional relationship of any kind between RelSci and Chi Hsien Chan.